ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Sells $60,200.00 in Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) SVP Krista Davis sold 1,000 shares of the stock in a transaction dated Friday, February 21st. The stock was sold at an average price of $60.20, for a total transaction of $60,200.00. Following the sale, the senior vice president now owns 68,624 shares in the company, valued at $4,131,164.80. The trade was a 1.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Krista Davis also recently made the following trade(s):

• On Wednesday, December 11th, Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $60.00, for a total transaction of $60,000.00.

ANI Pharmaceuticals Trading Up 0.9 %

ANIP opened at $55.01 on Thursday. The company’s 50 day moving average is $57.06 and its 200-day moving average is $58.15. ANI Pharmaceuticals, Inc. has a 1-year low of $52.50 and a 1-year high of $70.81. The company has a current ratio of 2.74, a quick ratio of 1.97 and a debt-to-equity ratio of 1.52. The company has a market cap of $1.16 billion, a P/E ratio of -100.02 and a beta of 0.74.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on ANIP. Leerink Partners began coverage on shares of ANI Pharmaceuticals in a research note on Wednesday, December 11th. They set an “outperform” rating and a $80.00 price objective on the stock. StockNews.com upgraded shares of ANI Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 5th. HC Wainwright reiterated a “buy” rating and set a $94.00 price objective on shares of ANI Pharmaceuticals in a research note on Monday, November 11th. Finally, Leerink Partnrs upgraded shares of ANI Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday, December 11th. Two research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, ANI Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus price target of $77.71.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ANIP. Assenagon Asset Management S.A. raised its holdings in ANI Pharmaceuticals by 149.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 186,179 shares of the specialty pharmaceutical company’s stock valued at $11,107,000 after buying an additional 111,613 shares during the last quarter. Louisiana State Employees Retirement System raised its holdings in ANI Pharmaceuticals by 3.9% in the 3rd quarter. Louisiana State Employees Retirement System now owns 8,000 shares of the specialty pharmaceutical company’s stock valued at $477,000 after buying an additional 300 shares during the last quarter. State of Alaska Department of Revenue raised its holdings in ANI Pharmaceuticals by 5.2% in the 3rd quarter. State of Alaska Department of Revenue now owns 9,467 shares of the specialty pharmaceutical company’s stock valued at $564,000 after buying an additional 464 shares during the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in ANI Pharmaceuticals by 64.2% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 4,045 shares of the specialty pharmaceutical company’s stock valued at $241,000 after buying an additional 1,582 shares during the last quarter. Finally, New York State Teachers Retirement System raised its holdings in ANI Pharmaceuticals by 1.7% in the 3rd quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company’s stock valued at $1,439,000 after buying an additional 394 shares during the last quarter. Institutional investors own 76.05% of the company’s stock.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.